論文

査読有り
2012年

Anti-Atherosclerotic Potential of Dihydropyridine Calcium Channel Blockers

JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS
  • Norio Ishii
  • ,
  • Takeshi Matsumura
  • ,
  • Seiya Shimoda
  • ,
  • Eiichi Araki

19
8
開始ページ
693
終了ページ
704
記述言語
英語
掲載種別
DOI
10.5551/jat.12450
出版者・発行元
JAPAN ATHEROSCLEROSIS SOC

Dihydropyridine calcium channel blockers (CCBs) are widely used agents for patients with hypertension. Dihydropyridine CCBs lower blood pressure mainly through vasodilation and reduction of peripheral resistance, and several clinical studies have demonstrated that they have clinical benefits in patients with cardiovascular diseases. In addition, some studies have indicated that dihydropyridine CCBs have anti-atherogenic effects beyond their blood pressure-lowering effects. In fact, several studies using atherosclerotic model animals have revealed that dihydropyridine CCBs suppress atherosclerotic lesion formation. It is well known that the production of reactive oxygen species (ROS) is involved in the progression of atherosclerosis by stimulating the production of inflammatory factors such as chemokines, cytokines and adhesion molecules. Dihydropyridine CCBs can suppress ROS generation and subsequent inflammatory actions in vascular cells and arterial walls. Furthermore, several reports have revealed that dihydropyridine CCBs suppress the expression of adhesion molecules, thereby inhibiting monocyte adhesion to endothelial cells, which is thought to be an early step in the pathogenesis of atherosclerosis. In smooth muscle cells, dihydropyridine CCBs suppress cell proliferation and migration in vitro and in vivo. In macrophages, dihydropyridine CCBs decrease cholesterol accumulation and intracellular cholesterol esterification, and increase cholesteryl ester hydrolysis. Moreover, dihydropyridine CCBs suppress the expression of matrix metalloproteinases, which affects the stability of atheromatous plaques. Interestingly, recent studies have revealed that the anti-atherosclerotic effects of dihydropyridine CCBs are mediated, at least in part, via the activation of peroxisome proliferator-activated receptor-gamma. In this review, we focus on the anti-atherosclerotic effects of dihydropyridine CCBs beyond their blood pressure-lowering effects.

リンク情報
DOI
https://doi.org/10.5551/jat.12450
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/22653165
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000308437400001&DestApp=WOS_CPL
ID情報
  • DOI : 10.5551/jat.12450
  • ISSN : 1340-3478
  • eISSN : 1880-3873
  • PubMed ID : 22653165
  • Web of Science ID : WOS:000308437400001

エクスポート
BibTeX RIS